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Evolution of contrast agents for
ultrasound imaging and
ultrasound-mediated drug delivery
Vera Paefgen, Dennis Doleschel and Fabian Kiessling*
Institute for Experimental Molecular Imaging, RWTH Aachen University Hospital, Aachen, Germany
Ultrasound (US) is one of the most frequently used diagnostic methods. It is a
non-invasive, comparably inexpensive imaging method with a broad spectrum of
applications, which can be increased even more by using bubbles as contrast agents
(CAs). There are various different types of bubbles: filled with different gases, composed
of soft- or hard-shell materials, and ranging in size from nano- to micrometers. These
intravascular CAs enable functional analyses, e.g., to acquire organ perfusion in real-
time. Molecular analyses are achieved by coupling specific ligands to the bubbles’
shell, which bind to marker molecules in the area of interest. Bubbles can also be
loaded with or attached to drugs, peptides or genes and can be destroyed by US
pulses to locally release the entrapped agent. Recent studies show that US CAs are
also valuable tools in hyperthermia-induced ablation therapy of tumors, or can increase
cellular uptake of locally released drugs by enhancing membrane permeability. This
review summarizes important steps in the development of US CAs and introduces the
current clinical applications of contrast-enhanced US. Additionally, an overview of the
recent developments in US probe design for functional and molecular diagnosis as well
as for drug delivery is given.
Keywords: ultrasound, contrast agent, microbubbles, nanobubbles, molecular imaging, drug delivery,
theranostics
Introduction
Ultrasound (US) imaging enables cheap, non-invasive imaging in real-time with a high soft tissue
contrast and without exposing the patient to radiation. This, together with its broad ﬁeld of
applications, explains the extensive use of clinical US imaging. Applications range from ﬁrst-
look examinations in abdomen or extremities to cardiac applications and endosonography, e.g.,
in the female genital tract. US regularly supplements x-ray mammography and it is used for
the assessment of tissue vascularization and of vessel occlusion using Doppler. In many cases,
additional CA are not needed to ﬁnd the right diagnosis. For poorly vascularized tumors or regions
withmany small vesselswith slow blood ﬂowDoppler US is not suﬃcient. Hence CEUS is an option
and was shown to improve cancer detection and tumor characterization, decreasing the number of
Abbreviations: BBB, blood-brain barrier; CA, contrast agent(s); CEUS, contrast-enhanced ultrasound; HIFU, high-intensity
focused ultrasound; HS-MB, hard-shell microbubble(s); LOFU, low-intensity focused ultrasound; MB, microbubble(s); NB,
nanobubble(s); PBCA, poly(n-butylcyanoacrylate); PEG, polyethylene glycol; PFC, perﬂuorocarbon(s); PLGA. poly(D,L-
lactide-co-glycolide); PVA, poly(vinyl-alcohol); SS-MB, soft-shell microbubble(s); tPA, tissue plasminogen activator; US,
ultrasound; USCA, ultrasound contrast agent(s); (U)SPIO, (ultrasmall) superparamagnetic iron oxide.
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biopsies, or during surgery in brain cancer patients (Kitano et al.,
2012; Uemura et al., 2013; Prada et al., 2014).
Application of CEUS started in the late 1960s after ﬁnding that
the injection of agitated saline caused a detectable signal change
during US examination (Gramiak and Shah, 1968). Contrast
enhancement was caused by the compressible gas core of saline
bubbles, enabling the bubble to backscatter the applied US
wave. Those ﬁrst saline bubbles were unstable due to the high
surface tension. By injection of autologous blood at adequately
rapid rates, the formation of more stable bubbles was described
(Kremkau et al., 1970), nonetheless those bubbles still lacked
suﬃcient lifetime and a deﬁned size. It took more than 20 years
to develop the ﬁrst stable, commercially available and FDA-
approved USCA (Feinstein et al., 1990), Albunex R©, an albumin-
coated and air-ﬁlled microsphere.
Since then, stability and biocompatibility of USCA have
been continuously improved and bubbles have been modiﬁed
to speciﬁcally target certain surface molecules expressed in
pathological alterations. Apart from their support for imaging
and diagnostics, micro- and NBs are object of increased interest
for therapeutic applications. Recent studies used the disrupting
eﬀect of MB-enhanced US on the BBB in combination with
transplantation of mesenchymal stem cells for treatment of brain
ischemia, or used MBs as carriers of drugs, siRNA and mRNA
(Dewitte et al., 2014; Gong et al., 2014). This broad ﬁeld of
diﬀerent uses makes USCA attractive for research and beneﬁcial
for patients. Currently three diﬀerent MB-based CA are clinically
approved in the United States/North America and Europe, and a
fourth is clinically used in Japan and South Korea, but the variety
among the investigative CA is much broader and frequently
produces new, promising progenies. Since examinations with
those approved CA are common in the clinics, guidelines
for CEUS imaging of the liver exist to guarantee proper and
comparable examinations and an improvement for the patients’
diagnosis and therapy (Claudon et al., 2013).
Diagnostics
Due to their broad applicability and low risks, many diﬀerent
types of USCA have been developed. To get started, an overview
of the diﬀerent possibilities to use bubbles of varying size, shell
material, or gas cores will be presented, as well as their properties,
applications, and advantages.
Microbubbles
The majority of USCA in use are MBs. As their name suggests,
their diameters range between 1 and 10 μm. This size normally
limits the application of MB to the intravascular system to assess
functional parameters like vascularity, perfusion, blood ﬂow
velocity, angiogenicity, or to characterize vasculature molecularly
by using targeted MB (Yuan and Rychak, 2013). Extravasation
of MB to surrounding tissue is inhibited, preventing unspeciﬁc
accumulation in the interstitial space and unwanted background
signals. Micron-sized bubbles were found to cause proper
backscattering of applied US pulses, not only with linear
oscillations, but also with non-linear ones, which are not strongly
present in most tissues. Thus, MB can be detected with high
sensitivity and a good contrast.
In this review we will introduce the main diﬀerent shell
materials, normally divided in soft- and hard-shell bubbles, will
be introduced. Even though the included gas is responsible for
the majority of the bubbles’ acoustic properties, the shell adds a
mechanical stiﬀness and reduces the compressibility of the gas.
Therefore, the shell material provides multiple possibilities to
tailor the MB to their speciﬁc application by changing visco-
elastic properties (Hoﬀ et al., 1996; Kiessling et al., 2014),
Nonetheless, the choice of gas is a factor that has to be
considered. First experiments used air, but still suﬀered from poor
stability and very short circulation times due to the high solubility
of air in water. The same diﬃculties occurred in tests using
a nitrogen ﬁlling, though a less gas-permeable coating slightly
improved lifetime (Unger et al., 1994; Schutt et al., 2003). It was
found that PFC were a good choice with their low solubility
in water/blood and their good compatibility. With introduction
of PFC it became possible to produce MB of a deﬁned size
with a lifetime of several minutes, long enough for diagnostic
examinations in vivo. To rule out possible changes in bubble-size
by air diﬀusing along the concentration gradient between blood
and bubble, MB can be produced with a deﬁned mixture of PFC
and air, so that Laplace and arterial pressure are in equilibrium
(Schutt et al., 1996). Another useful side eﬀect of using PFC is the
possible application of those USCA for MRI, since ﬂuorine (19F)
is NMR-detectable, even with a normal, slightly adjusted proton
setup (Siemens TIM Trio 3T MRI scanner, transmit/receive
19F/1H dual-tune volume RF coil, a pre-ampliﬁer), and does
not cause background signals in patients (Rapoport et al., 2011).
However, the amount of ﬂuorine to detect is extremely small and
requires a highly sensitive setup.
Hard-Shell Microbubbles
The group of HS-MBs mainly consists of gas bubbles with
a coating of lower visco-elastical properties such as polymers
or denatured proteins, as well as porous silica materials
encapsulating gas. Generally, HS-MB show an increased
circulation time in vivo and are the preferred type of CA for
higher-intensity US applications where they provide a higher
echogenicity than SS-MBs which might rupture.
Polymer-shelled microbubbles
The ﬁrst polymers used for US applications were naturally
occurring air-ﬁlled polymers. Gelatin was among the ﬁrst
biopolymers to be tested, but the production of adequately small
MB turned out to be diﬃcult and their circulation time was
short (Carroll et al., 1980). Wheatley et al. (1990) pointed out
the lack of appropriate CA for US diagnostics 20 years after the
discovery of gas bubbles as a suitable system. They developed a
setup for alginate-air MB, but again struggled with the needed
maximal size of approximately 10 μm (Wheatley et al., 1990).
Other approaches used agarose gel as shell material (D’Arrigo,
1981) with similar complications. For all natural polymers an
increased risk of material contaminations was found, in addition
to decreased reproducibility of size-deﬁned bubbles and adequate
in vivo stability to enable clinical examinations (Cohen et al.,
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1996; Schutt et al., 2003). Until today, there are no clinically
approved CA derived from those natural polymers, though a
few groups still work with those materials due to their good
compatibility (Huang et al., 2013). By switching to synthetic
polymers, the risk of contamination could be decreased andmany
of them have proven their biocompatibility in other applications
(Kelly et al., 2003). Modern polymer-shelled MB are normally
made of synthetic polymers with a PFC/air-ﬁlling.
Cyanoacrylate polymers were ﬁrst used as a shell material
by Fritzsch et al. (1994). Under the name SHU 563 A, later
on Sonovist R© , (Schering AG, Berlin), those air-ﬁlled MB were
shown to last more than 10 min in vivo, both in animals
and in patients, to have a good biocompatibility and to be
taken up by the reticuloendothelial system eﬀectively. These
properties made SHU 563 A an interesting tool for liver and
spleen US examination (Bauer et al., 1999; Forsberg et al., 1999).
Apart from Sonovist R© , other cyanoacrylates are investigated for
US applications as well. PBCA is a well-known biocompatible
polymer and, as a gas-ﬁlled MB, tested for various diagnostic or
therapeutic US-supporting applications. Synthesis of PBCA-MB
includes intensive stirring during polymerization in presence of
a detergent like Triton X-100 and hydrochloric acid (pH = 2).
Olbrich et al. (2006) compared one- and two-step synthesis
protocols and stirring intensity to vary size, shell thickness and
the resulting properties of MB under acoustic pressure, as well
as the MB survival time in plasma and serum. Factors that
might interfere with MB stability were high injection rates and
small needle diameters during MB injection, but when handled
and stored correctly, PBCA-MB remained stable for multiple
weeks (Fokong et al., 2011). Besides using PBCA-MB for drug
delivery in therapeutic approaches, they can also be labeled with
ﬂuorophores or iron nanoparticles and thus be a useful tool
for multimodal imaging with US and 2-photon-/ﬂuorescence
microscopy or MRI (Koczera et al., 2012; Lammers et al., 2015).
Poly(D,L-lactide-co-glycolide) is another commonly used
material for MB synthesis. Here, bubbles are produced from a
double emulsion of water, oil, and water, followed by evaporation
of solvents. Compared to PLLA, PLGA has a faster degradation
rate (Cui et al., 2005a). By varying factors like the molecular
weight or adding capping structures to the polymers’ ends, US
scattering properties could be adjusted (Eisenbrey et al., 2008).
Among the ﬁrst animal experiments for PLGA-MB, myocardial
contrast echocardiography was successfully done in dogs (Cui
et al., 2005b). More recent approaches make use of PLGA-MB as
delivery vectors, often in tumor treatment. Niu et al. (2012, 2013)
used PLGA-MB to support identiﬁcation of lymph nodes near
tumor sides during surgery by delivering Sudan black, as well
as the chemotherapeutic drug doxorubicin and iron particles, to
make use of both US and MRI evaluation. PLGA-MB have been
used as CA with sonosensitizer properties for tumor treatment as
well, when coupled to hematoporphyrin that gets activated by US
and is supposed to induce tumor necrosis (Zheng et al., 2012).
Nonetheless there are currently no FDA-approved PLGA-MB for
clinical applications.
Poly(vinyl-alcohol) is characterized by a good
biocompatibility and its hydroxylic moiety which allows
multiple chemical modiﬁcations (Cavalieri et al., 2005). Around
10 years ago several groups started working on PVA-MB. Similar
to PBCA-MB, bubbles are synthesized during high stirring and
in presence of hydrochloric acid, but due to its water soluble
character, no detergent is needed, therefore the crosslinking
occurs at the water/air interface (Cavalieri et al., 2006). By slight
variations of temperature and pH value in the synthesis phase,
the bubbles’ diameter could be changed. PVA-MB were able to
produce signal enhancements up to 20 dB in suspensions and
have successfully been combined with SPIO nanoparticles to
enable multimodal imaging (Grishenkov et al., 2009; Brismar
et al., 2012).
Finally, MB can be produced by ink-jet printing using a
polyperﬂuorooctyloxycaronyl-poly(lactic acid) copolymer. The
printing method allows to speciﬁcally generate bubbles of a
deﬁned size and thus studies of swelling or shrinking processes
(Böhmer et al., 2006, 2010).
Protein-shelled microbubbles
Though less resistant to US waves than polymer-coated MB,
but with a longer history of use and development, the ﬁrst
commercially available USCA was the protein-shelled MB
Albunex R© (Molecular Biosystems, San Diego, CA, USA). On
their way to develop a useful USCA for clinical applications,
Keller et al. (1987) discovered that a 5% heat-denatured human
albumin solution after sonication produces adequately stabilized,
air-ﬁlled bubbles of mostly less than 10 μm in diameter.
First animal experiments showed an enhanced contrast in
2D echocardiography after intravenous injection (Keller et al.,
1987) and a behavior similar to erythrocytes to guarantee no
interferences in coronary ﬂow or hemodynamics caused by the
CA during myocardial US examination (Keller et al., 1988, 1989).
Still, Albunex R© had a very limited lifetime in vivo due to its
air-ﬁlled core, and the general principle of albumin-shelled MB
was soon reﬁned by replacing air with perﬂuoropropane. This
was the beginning of the ‘second generation’ USCA Optison R©
(GE Healthcare, Buckinghamshire, UK). With a diameter of
2–5 μm, a shell thickness of approximately 15 nm, similar
to its predecessor, but consisting of only 1% albumin, clinical
trials proved a prolonged and better contrast enhancement
compared to Albunex R©, and a high preference of physicians
for Optison R© in left ventricular echocardiography (Cohen
et al., 1998). Optison R© under US application has been used
for temporary disruption of the BBB, though side eﬀects like
vasoconstriction and hemorrhages might occur with sub-optimal
US setting (Hynynen et al., 2001; Raymond et al., 2007). For
echocardiography, application of Optison R© was found to be
generally safe in patients with diﬀerent cardiologic problems,
and potential induction of myocardial necrosis was ruled out
(Borges et al., 2002; Wei et al., 2014). Nonetheless, in patients
with an unstable cardiopulmonary status or an acute myocardial
infarction, application is contraindicated (Dolan et al., 2009).
Soltani et al. (2011) tested a mixture of tPA and the CA
Optison R© and the soft-shell MB SonoVue R© (now Lumason R©,
Bracco, Milano, Italy) in a diﬀerent setup. Using a catheter
as a model of human vessels, they treated in vitro an acute
ischemic stroke via intra-arterial sonothrombolysis, suggesting
an eﬀective treatment for some stroke patients (Soltani et al.,
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2011). Optison R© is FDA-approved for cardiac applications such
as left ventricular opaﬁcation and endocardial border deﬁnition.
Like polymer-shelled MB, it was shown by Korpanty et al. (2005)
to use albumin-based MB, here in combination with dextrose,
for molecular targeting. Avidin was incorporated in the shell, so
that biotinylated antibodies could be bound functionally to the
bubbles (Korpanty et al., 2005). Another more recent approach
uses targeted poly-D,L-lactide/albumin hybrid MB for diﬀerential
diagnosis in patients with chest pain to detect recent ischemia
(Leng et al., 2014).
Soft-Shell Microbubbles
Soft-shell MB are commonly used for examinations using a low
mechanical index (MI) since these MB are sensitively detectable
by their non-linear oscillations. The better oscillation properties
of SS-MB compared with HS-MB are due to the thinner,
more ﬂexible shells, which are held together not by covalent
bonding, but hydrophobic interactions. Therefore, after slight
shell disruptions, the shell seals itself to minimize surface tension
(Borden et al., 2005; Brismar et al., 2012). If sealing is not possible
due to the high acoustic pressure, the MB will split into several
smaller bubbles instead of bursting like HS-MB (Figure 1). To
achieve optimal contrast, the shells’ characteristics should be
considered and the acoustic power adjusted to the type of MB
(Leong-Poi et al., 2002).
The most common shell materials for SS-MB are surfactant
molecules or phospholipids, where the length of the acyl chain
mainly inﬂuences the bubbles’ acoustic dissolution and the
monolayers’ cohesiveness (Borden et al., 2005).
Phospholipid microbubbles
Several patents fromUnger et al. (1994) describe early approaches
for the synthesis of SS-MB and handling of gas-ﬁlled liposomes
with a diameter of approximately 2 μm. Those liposomes were
easy to produce by just adding the phospholipid of choice to
water or buﬀer of the temperature slightly above the lipids’
transition point from gel to a liquid crystalline state in which the
liposomes form, cooling it back down and removing the liquid by
negative pressure application (Unger, 1994). Dried liposomes, in
presence of protectants such as trehalose, were found to have a
greatly increased shelf life stability and to regain their shape and
functionality when reﬁlled with gas again (Crowe et al., 1985).
FIGURE 1 | Behavior of SS-MB (lipid) and HS-MB (polymer) at different
US intensities (modified from Hernot and Klibanov, 2008).
Upscaling production of lipid-layer MB, as well as the use of those
bubbles for multimodal imaging via inclusion of paramagnetic
particles such as gadolinium in the bubbles for MRI has been
patented by D’Arrigo (1993), who also described the potential of
MB for tumor treatment, even in the brain (D’Arrigo, 1993).
The ﬁrst lipid-based USCA that made it to clinical trials
and the clinics was Perﬂutren, sold as Deﬁnity R© or Luminity R©
(Lantheus Medical Imaging, North Billerica, MA, USA). It
contains perﬂuoropropane-ﬁlled MB in a shell made of three
diﬀerent saturated 16-carbon-long phospholipids. With an
average size between only 1–2 μm they are smaller than most
HS-MB (Unger et al., 2004). During the trial phase, a good
compatibility was seen, as well as left ventricular cavity and
myocardial enhancement (Fritz et al., 1997). Despite being
developed and FDA approved primarily for echocardiography
and cardiologic application, studies showed further clinical
applications (Barr, 2013), such as their use to improve detection
of tumors, e.g., in the liver. It takes a few minutes to examine a
whole liver with US, but theMB lifetime of approximately 3.5min
after bolus injection was found to be suﬃcient. Compared to
non-CEUS, the usage of Deﬁnity R© showed a higher reliability in
tumor- and nodule detection in the liver of rabbits, though the
CA itself does not accumulate in the liver (Maruyama et al., 2005).
Similar to HS-MB, lipid-based MB have been found to be
useful for therapeutic applications. Integration of lipophilic
drugs in the shell, coupling to the outer side of the shell, or
encapsulation of therapeutic agents have been shown and are
under development for US-assisted and guided therapy, i.e., in
cancer treatment. They have also been successfully tested for
thrombolysis in combination with US and thrombolytic agents
(Unger et al., 2004). More about therapeutical applications will
be described later on (see Bubbles as Therapeutics).
Apart from Deﬁnity R©/Luminity R© , another SS-MB has clinical
approval for cardiologic applications. SonoVue R© (Bracco
Imaging) gained FDA-approval in 2001 and, after a withdrawal,
again in 2014, now under the name Lumason R©. This sulfur
hexaﬂuoride ﬁlled phospholipid-MB are generally used for
left ventricular opaﬁcation and endocardial border deﬁnition,
but in some countries also have approval for general vessel
diagnostic or imaging of microvascular structures in the breast
or diﬀerentiation of lesions in the liver (Claudon et al., 2013;
Appis et al., 2015). Apart from that, SonoVue R© has also
been tested in clinical trials for monitoring of uterine ﬁbroid
vascularization and improved ablation (Henri et al., 2014; Jiang
et al., 2014).
Surfactant-stabilized microbubbles
Hilmann et al. (1985) already suggested the usage of surfactant-
stabilized gaseous MB for US diagnostics, but it was not before
the mid-90s that this method found its way into more clinically-
related in vitro research. Among the ﬁrst surfactant-stabilized MB
were those derived from a mixture of the non-ionic surfactants
Span60 (sorbitan monostearat) and Tween80 (polyoxyethylene
sorbitan monooleate) in diﬀerent molar ratios, but also other
members of the Span/Tween family. MBs of a diameter below the
maximum of 10 μm were obtainable and for certain mixtures a
shelf time of several weeks and a high echogenicity in B-mode
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US imaging were shown (Singhal et al., 1993; Wheatley et al.,
1994). Still, those MB that succeeded in clinical trials were of
diﬀerent materials. Imagent R© (IMCOR Pharmaceuticals Inc., San
Diego, CA, USA) MB of approximately 5 μm in diameter, ﬁlled
with a mixture of air and PFCs, were ﬁrst tested for renal and
liver perfusion studies in rabbits, later for myocardial perfusion
and detection of general blood ﬂow abnormalities using Doppler
US. It showed promising contrast and compatibility with almost
no adverse side eﬀects in ﬁrst clinical trials (Taylor et al., 1996;
Sirlin et al., 1997; Pelura, 1998). Nonetheless other CA from this
family dominated and still dominate, both in research and in the
clinics. One of them, Levovist R© (Schering AG, Berlin, Germany)
or SHU-508, was developed in the late 1980s and has been tested
and used for several applications since then. Consisting of a
saccharide- and palmitic acid-containing shell and air-ﬁlled in
early versions, it was ﬁrst tested for examinations of the left
ventricle in dogs. A huge advantage was the mean size below
6 μm and the described transpulmonary circulation, making
intravenous injections possible and injections directly into the
left heart chamber superﬂuous, (Smith et al., 1989). Clinical
trials on echocardiography in patients showed good contrast
enhancement and only minor adverse side eﬀects (Schlief
et al., 1991). In patients with liver metastases Levovist R© greatly
enhanced the visualization of blood ﬂow in the tumors, which
led to a better diﬀerentiation between cancer, hemangiomas
and fatty lesions (Ernst et al., 1997). Similarly, more recent
studies investigated the advantages of CEUS using Levovist R© for
diﬀerentiation between benign and malignant tumors in several
organs, such as spleen, breast, and ovaries. A clear diﬀerentiation
between malignant and benign tumors was possible, which led
to the conclusion that CEUS with Levovist R© can help to avoid
unnecessary biopsies and surgeries (Ota andOno, 2004;Wu et al.,
2015).
The other main player in the ﬁeld of surfactant-stabilized MB
is Echogen R© (Sonus Pharmaceuticals, Bothel, WA, USA) with
a core of dodecaﬂuorpentane. First described by Cotter et al.
(1994) it quickly became an object of interest (Kronzon et al.,
1994). Dodecaﬂuorpentane has a boiling point of approximately
29◦C, so it can be injected intravenously as nano-sized, non-
echogenic liquid droplets, and immediately transit to echogenic
bubbles of 1–2 μm (Forsberg et al., 1994). In direct comparison
with Albunex R© for echocardiography, the dodecaﬂuorpentane-
based CA was found to lead to better results regarding
enhancement duration, endocardial border delineation and
diagnostic conﬁdence (Grayburn et al., 1998). However, among
the surfactant-stabilized MB, Levovist R© was the more common,
especially since it received approval for clinical applications
and in Europe and Canada, whereas Sonus Pharmaceuticals
stated withdrawal of their application for FDA approval in
2000 (Correas et al., 2014). By now, Levovist R© is not approved
anymore for clinical use either. A list of USCA which have/had
clinical approval is given in Table 1.
Nanobubbles
Due to their size, MB are unable to leave the vasculature,
even in solid tumors, which often have leaky vasculature and
a poor lymphatic drainage. This leads to extravasation and
retention of macromolecules, also known as the EPR eﬀect
(enhanced permeability and retention). To extravasate to the
tumor itself, bubbles need to be smaller than 400–800 nm
in diameter, therefore referred to as NBs. It has been shown
that even bubbles of this dimension were able to produce
an enhanced backscatter after US application (Oeﬃnger
and Wheatley, 2004). Additionally, high accumulation of
NB in tumors was described, also referred to as passive
targeting (Yin et al., 2012). Enhancement of more than
20 dB could be detected for several minutes in vitro, using
NB of approximately 500 nm in size and being composed
of a Span60/Tween80 shell and octaﬂuoropropane as a
gaseous core. However, similar to experiments with MB
derived from Span60/Tween80, some adverse side eﬀects
such as tachycardia were seen in patients due to the limited
biocompatibility of the material. Using the highly compatible
polyoxyethylene-40-stearate as a substitute for Tween80 to
create a “parents suspension” with MB and separation of
NB populations by centrifugation led to the development
of biocompatible NB of 400-600 nm size. Extravasation
into the tumor tissue and contrast enhancement for several
minutes was seen using power Doppler (Xing et al., 2010).
In diﬀerent approaches, PLGA and PBCA instead of
surfactants have been used to develop biocompatible NB
between 150–450 nm (300–500 nm, respectively) in diameter
that have been labeled with antibodies binding to HLA-G
or TAG-72 to speciﬁcally bind to tumors deriving from
trophoblastic or epithelial tissue (Xu et al., 2010; Zhang et al.,
2014).
Regarding in vivo lifetime of NB, results from diﬀerent
studies vary between a few minutes to more than 1 h of
contrast enhancement (du Toit et al., 2011; Yin et al., 2012).
The size of NB, their material composition and additional
coatings or added ligands strongly inﬂuence the circulation
time and their uptake by the reticuloendothelial system, so that
for each NB formulation this factor needs to be determined
individually.
If exclusively imaging is wanted, MB still are the ﬁrst choice
due to their higher gaseous content and better oscillation.
Nonetheless, accumulation of PFC-containing nanodroplets in
the tumor interstitium and US-induced fusion of droplets into
MB has been reported (Rapoport et al., 2011). Additionally
injection of a nanoparticle emulsion with a generally poor
acoustic reﬂectivity strongly enhances US-contrast when bound
in great numbers to speciﬁc target sites (Lanza et al.,
2000). However, NB are of high interest for therapeutic
approaches such as thermal sensitizers in tumors that undergo
radiofrequency treatment (Perera et al., 2014). When ﬁlled
with or coupled to drugs, generally for cancer treatment,
the passive targeting to the tumor and the EPR eﬀect
might be used for more speciﬁc drug delivery and enhanced
therapeutic success. Additionally, several groups are also
working on the development of targeted, drug-, nucleic acid-
ﬁlled, or drug-free NBs, directed against diﬀerent tumor
markers.
The current state of the art and preclinical studies with NB will
be described later on.
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TABLE 1 | Ultrasound contrast agent that have/had been clinically approved.
Name First approved
for clinical use
Shell material Gas Application (examples) Producer/distributor Countries
Optison 1998 Cross-linked
serum albumin
Octafluoropropane Left ventricular opafication GE healthcare,
Buckinghamshire, UK
US, Europe
Sonazoid 2007 Phospholipid Perfluorobutane Myocardial perfusion, liver
imaging
GE healthcare,
Buckinghamshire, UK/
Daiichi Saniko, Tokyo, JP
Japan, South
Korea
Lumason/SonoVue 2001/2014 Phospholipid Sulphurhexafluoride Left ventricular
opafication, microvascular
enhancement (liver and
breast lesion detection)
Bracco diagnostics,
Milano, Italy
US, Europe,
China
Definity/Luminity 2001/2006 Phospholipid Octafluoropropane Echocardiography,
liver/kidney imaging
(Canada)
Lantheus medical
Imaging, North Billerica,
MA
North America,
Europe (approval
filed)
Imagent/Imavist 2002, withdrawn Phospholipid Perfluorohexane,
Nitrogen
Echocardiography, heart
perfusion, tumor/blood
flow anomalies
Schering AG, Berlin, DE US
Echovist 1991, withdrawn Galactose
microparticles
Air Right heart imaging Schering AG, Berlin, DE Germany, UK
Levovist 1995, withdrawn Galactose
microparticles,
palmitic acid
Air Whole heart imaging,
doppler imaging
Schering AG, Berlin, DE Canada, Europe,
China, Japan
Albunex 1993, withdrawn Sonicated
serum albumin
air Transpulmonary imaging Molecular Biosystems
Inc., San Diego, CA, USA
Japan, US
Silica Shells
With a size between 0.2–2 μm, silica hard-shell particles cannot
be placed uniformly in the groups of MB or NB, nor can they
be called bubbles, but they are an interesting and new USCA
as well. Their rise started around 2009 when Lin et al. (2009)
showed their ﬁrst experiments with gas-ﬁlled silica shells in vitro.
A high MI is required to rupture the shells, releasing the gas of
the porous particles and thus produce an US-detectable signal
(Lin et al., 2009). Synthesis of silica shells is more complicated
compared to other USCA, as it requires templates, generally
polystyrene particles, which have to be removed by suitable
solvents and replaced by PFCs afterward. After evaluation of
possible cytotoxic or hemolytic eﬀects of clinically reasonable
concentrations, silica shells were injected in rat testicles and
detected with US at varyingMI (Hu et al., 2011a). A clearly visible
contrast enhancement was seen up to 20 min after injection.
In a murine cancer model silica micro- and nano-shells were
injected intraperitoneally and imaged using a MI of 1.9 which
destroyed the shells and led to detectable “Loss of correlation”
signals, when the air sucked out of the particle shell. After image
processing steps for motion correction and threshold-, median-
and high-pass ﬁlter application the high background signals
could be subtracted and the accumulation of silica shells in the
tumor could be reliably detected (Ta et al., 2012). Liberman et al.
(2012, 2014) suggested the usage of silica micro-shells for labeling
breast tumors. In their study, the shells were shown to stay in
place and being detectable after a local injection for more than
1 day, providing an alternative to guiding wires which are clinical
standard. Additionally, those silica particles were found to be
promising sonosensitizers in US-mediated ablation therapies in
ex vivo and some ﬁrst in vivo experiments (Liberman et al., 2012,
2014), whereas another approach combined silica-coated shells
with PFC-ﬁlling and additionally an included chemotherapeutic
drug. With a USCA like that, imaging, ablation and drug delivery
would be possible at the same time, but further development is
needed here (Ma et al., 2014).
Similar to bubble CA, researchers work on modiﬁcations of
silica shells for speciﬁc targeting. A ﬁrst attempt of micron-sized
shells with a functionalization involved the addition of an amino
(−NH2) group (Hu et al., 2011b). In their publication they also
describe a simple way to control the shells’ diameter and thickness
by variation of tetraethylorthosilicate content. Another approach
to modify silica particles involves conjugation of hollow silica
nano-sized spheres to Gd-DTPA and cycloRGD. This construct
has been tested successfully in a murine tumor model for targeted
tumor imaging with MRI and US, but animals have only been
observed for 8 h after injection and long-term studies will be
needed for a proper evaluation (An et al., 2014).
Biodistribution and Degradation
For the development of new CA, often clinically approved or
as biocompatible considered biomaterials are chosen. Parallel to
the investigation of the material’s behavior in its bubble/particle
shape under US application, in vitro toxicity and stability tests
under physiological conditions need to be done. Here, ﬁrst
experiments with the CA in presence of blood can be made to
rule out potential hemolytic eﬀects of MB under US application
(Dalecki, 2005), or a low stability when confronted with blood.
For the gaseous ﬁlling, it has been shown that PFC as not-
naturally in living organisms existing gases, are biologically
inert and completely excreted by exhalation within less than
1 day without undergoing modiﬁcation (Hutter et al., 1999;
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Hvattum et al., 2001; Toft et al., 2006). Clearance of the shell
material happens via the reticuloendothelial system, namely liver
and spleen, where macrophages engulf what is left after the
gaseous content left the shell by diﬀusion. Renal clearance has
not been reported for clinically approved USCA, which makes
CEUS a suitable diagnostic tool also in patients with renal
insuﬃciency, without the need for other examinations and before
CA application. Temporary pain in the kidney area after CA
injection is most likely caused by the MBs’ accumulation in the
small renal vessels, though an eﬀect on blood circulation and
function could not be found (Cokkinos et al., 2013; Liu et al.,
2013). To the best of our knowledge, a broad comparison study
of the exact degradation and clearance processes of the most
common USCA has not been done so far, most likely because
severe side eﬀects rarely occur and long term impairments have
not been described.
Not only degassed, empty shells and fragments, but also
intact MB can be taken up by Kupﬀer cells in the liver, and
similar observations have been made for other macrophage
populations and neutrophils outside of the liver as well (Kindberg
et al., 2003) for Sonazoid R© (GE Healthcare, Buckinghamshire,
UK). The general tendency to enhance signal in the liver after
injection is best known for Levovist R©, but also Sonazoid R© and
Optison R© , and enables detection of liver and spleen anomalies,
whereas SonoVue R© and Imavist R© (Alliance Pharmaceuticals
Corp., Chippenham, UK) show little to no uptake by Kupﬀer
cells (Albrecht et al., 2000; Wilson et al., 2000). Due to an
accumulation of these CA in the smaller vessels of the liver
and a reduced blood ﬂow velocity, both blood pool CA can
be used for diﬀerentiation of benign and malign liver lesions
anyway (Maruyama et al., 2004; von Herbay et al., 2004; Quaia,
2006; Yanagisawa et al., 2007). Shell composition, size and
surface properties are responsible for their circulation time and
uptake by phagocytes, and no general behavior for phospholipid-
or protein-based bubbles can be predicted. So even between
materials from the same shell material ‘family’, diﬀerences can
be seen, most likely due to activation of the complement-system
by slightly diﬀerent surface structures (Chen and Borden, 2011;
Kiessling et al., 2012). For unbound bubbles, clearance via the
reticuloendothelial system normally happens within the ﬁrst
10 min after injection (Yuan and Rychak, 2013). To reduce
the fast uptake, addition of PEG to the outer surface can help
to prolong circulation time and further improve the general
biocompatibility (Ryan et al., 2008; Chen and Borden, 2011).
For polymer-coated MB, currently not clinically approved, renal
excretion after shell breakdown (Palmowski et al., 2008) has been
described and for some nanoparticles, excretion by the renal and
hepatic system by feces has been shown, though leftovers were
still detectable in animals after 3 months (Chen et al., 2013).
Micro- and NB were applied in patients with impaired
organ function without mentionable side eﬀects (Albrecht et al.,
2004). SonoVue R© has been tested in patients with chronic
obstructive pulmonary disease without showing more than
temporary light impairments like headaches, rushes, or dizziness
(Bokor et al., 2001). The theoretical risk of MB injections
in patients with coronary diseases is known and premature
ventricular contractions have been documented, especially at
higher MI and mostly after continuous injection instead of a
bolus injection. Adverse eﬀects though are rare and generally
mild and temporary, and unlike other imaging modalities, USCA
have been safely applied to patients with renal diseases, kidney
failure or a generally very bad health condition without an
increase in side eﬀects. In at least three cases, however, patients
died after SonoVue R© injection, but it is uncertain if the CA
injections caused the events (van der Wouw et al., 2000; ter Haar,
2009; Wei et al., 2014).
Active and Passive Targeting
As mentioned before, the EPR eﬀect enables the accumulation of
NB in the tissue of tumors, without any speciﬁc modiﬁcations
or targeting molecules. This type of contrast enhancement
or drug accumulation in the tissue is therefore referred to
as passive targeting (Yin et al., 2012). However, also MB
can be used up to a certain point for passive targeting.
The chemical composition of the shell aﬀects its behavior
in the body, causing accumulations in tissues or attachment
to cells. For example, Lindner et al. (2000a) were able to
show binding of albumin- and lipid-shelled MB to activated
leukocytes adherent to the venular wall without further
speciﬁc targeting moieties in an inﬂammation model. Binding
was mediated by β2-integrin and the complement system
(Lindner et al., 2000a). The same group also demonstrated that
incorporation of phosphatidylserine in the lipid shell enables
binding to activated leukocytes in inﬂammation (Lindner et al.,
2000b).
Active targeting requires speciﬁc surface modiﬁcation.
Since MB are limited to the vascular compartment, their
targets need to be expressed on the luminal side of endothelial
cells in pathological environments (Figure 2). Therefore, the
ﬁrst approaches toward targeted MB aimed for thrombosis
diagnostics and investigated the blood clot dissolving properties
of US application. Unger et al. (1998, 2000) used for their
ﬁrst in vitro system the shortest functional peptide sequence
of ﬁbrinogen, known to bind to glycoprotein IIb/IIIa on
platelets, and linked it to a lipid-shell bubble. In a binding
assay, they observed both binding and signal enhancement.
Their ﬁrst in vivo studies in a dog model showed similarly
promising results (Unger et al., 1998, 2000). Other early
approaches involved targeting the intercellular adhesion
molecule 1 (ICAM-1) for the detection of atherogenesis.
Villanueva et al. (1998) used an anti-ICAM-1 antibody covalently
bound to a lipid-shell bubble, showing a 40-times higher
adhesion of labeled bubbles to interleukin-1β-activated
ICAM-1 overexpressing endothelial cells in an in vitro
ﬂow system, compared to untreated endothelial cells. For
a ﬁrst in vivo approach, a rat model of heterotopic heart
transplant rejection was chosen. Both successful binding and
a strong US contrast enhancement were demonstrated in the
transplanted organ undergoing acute rejection (Weller et al.,
2003).
Amarker of angiogenesis in tumors is integrin αVβ3 expressed
by proliferating and activated endothelial cells. To speciﬁcally
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FIGURE 2 | Active targeting by coupling of ligands to MB that bind to structures overexpressed or exclusively expressed on tumor endothelium
(schematic illustration, not drawn to scale).
target tumors, antibodies binding to the αV-integrin subunit
were linked to MB and injected in mice that underwent local
growth factor treatment to induce neovascularization at the
injection site, and thus endothelial activation. A signiﬁcantly
greater amount of MB was found in this area, as well as a higher
acoustic activity (Leong-Poi, 2002). Short peptide sequences like
RGD can be used instead of αV-integrin-antibodies. In a murine
Met-1 breast cancer model, Ellegala et al. (2003) were able to
show similar results with MB linked to the integrin-recognition
peptide sequence RGD, and suggested αVβ3-targeted MB for
early tumor angiogenesis detection. Similar to αVβ3, the vascular
endothelial growth factor receptor 2 (VEGFR2) is commonly
expressed on activated, proliferating endothelial cells, which
makes it another target of interest for the detection of tumor
angiogenesis. VEGFR2 was successfully targeted with lipid-shell
MB in tumor models (Willmann et al., 2008). However, in a
murine model αV and VEGFR2 performed poorly as markers for
evaluation of early response to treatment. In this study, endoglin
was found to be a more suitable target molecule (Leguerney et al.,
2015).
Alternatively, Fokong et al. (2013) linked the peptide
sequence IELLQAR to PBCA-MB and achieved a strong contrast
enhancement in a murine breast cancer model due to the MB
binding to E-selectin, a marker of vascular inﬂammation and
early angiogenesis. Despite many positive pre-clinical studies,
evaluation in patients still has to be done. Here, it has to be
considered that the recognition motif to the MB which leads to
immunogenic responses in patients.
Active targeting has also been tested for NB. The principle is
the same, but contrary to MB, NB can also target receptors and
other molecules outside the endothelium due to their possible
extravasation to the tumor tissue (Figure 3). Functional coupling
of an antibody, in this case directed against the TAG-72 antigen
overexpressed on several epithelial tumors, to polymer-coated
NB and successful binding of those to cancer cells in vitro
has been shown by Xu et al. (2010). The usefulness of such
an approach for tumor treatment has also been demonstrated
in vivo using HLA-G as a target for antibody-coupled polymer-
NB (Zhang et al., 2014). The combination of HIFU and the
local release of chemotherapeutics after bubble disruption was
shown to strongly enhance apoptosis of tumor cells. Recently
Jiang et al. (2015) presented a promising new construct for
tumor imaging, improving the idea and the in vitro model
of Liu et al. (2007). Their lipid-based NB were coupled to
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FIGURE 3 | Passive targeting is enabled by ‘leaky’ vessels with fenestrae up to several 100 nm in tumor-associated endothelium and a poor
lymphatic drainage, increasing both likelihood and retention time of nano-sized particles in the interstitium (EPR effect). After extravasation,
NB/particles could also actively target specific surface molecules on cancer cells (schematic illustration, not drawn to scale).
Herceptin R© (Roche, Basel, CH), also known as trastuzumab, a
therapeutic monoclonal antibody binding to Her-2, which is
overexpressed in many breast tumors. They found a signiﬁcant
increase in NB-binding to the tumor in xenograft-models which
are known to overexpress Her-2, but only little accumulation
in tumor xenografts with low Her-2 expression. Targeted NB
in Her-2 overexpressing tumors also had an increased washout
half-time, enabling longer observation times. Additionally, their
bubble-construct was found to be of a low cytotoxicity (Jiang
et al., 2015). To this date, this might be the approach being the
closest to clinical studies. Herceptin R© has also been conjugated
to mesoporous silica nanoparticles and showed tumor-speciﬁc
toxicity in vitro, suggesting further development of silica particles
in the ﬁeld of targeted imaging and drug delivery (Milgroom
et al., 2014).
Bubbles as Therapeutics
The basic idea behind using MB for therapeutic purposes is
their ability to enhance vibration-eﬀects generated by US pulses.
Already Tachibana and Tachibana (1995) observed that US-
mediated thrombolysis is more eﬀective in the presence of
bubbles, resulting from acoustic cavitation of the sonicated
bubbles. Then, Molina et al. (2006) could demonstrate in a
clinical study on stroke patients that the rate of complete
arterial recanalization after soniﬁcation was signiﬁcantly higher
in the group that received MB and tPA, compared to only
tPA. Similar results were found in a sonothrombolysis trial with
transcranial US (Molina et al., 2009). Thus, the application of
MB to enhance US-mediated thrombolysis has the potential for
improving therapy of acute stroke patients (Tsivgoulis et al.,
2010). Recent results from Petit et al. (2015). support the
claim of strong synergistic eﬀects when US, MB, and tPA are
combined due to an enhanced clot lysis and degradation of
ﬁbrin.
Another application area for USCA as therapeutics is HIFU-
based tumor ablation. In the non-contrast-enhanced setting,
this is facilitated by thermal and mechanical eﬀects in the
target tissue arising from absorption of high-frequency US
waves and the internal conversion into heat and vibration,
including acoustic cavitation and radiation forces (Saha et al.,
2014). The group of Jiang et al. (2014) could demonstrate
in a clinical study that the additional administration of MB
(SonoVue R©) to patients prior to HIFU ablation increased the
HIFU-mediated tumor ablation signiﬁcantly more than solely
HIFU, even at lower soniﬁcation power and less soniﬁcation time.
The mechanism of the bubble-enhanced HIFU-mediated tissue
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ablation is suspected to be a result of the violent bubble collapse,
which may cause mechanical injury in the target tissue (Farny
et al., 2010).
A further application area for USCA as therapeutics is
sonoporation. LOFU pulses mediate temporal permeabilization
of cell membranes and enable drug delivery across biological
barriers like blood vessels or even the BBB (Kiessling et al., 2012).
Without bubbles, the low-intensity acoustic US-ﬁeld promotes
inertial cavitation, resulting in gas bubble creation, leading to
streaming and radiation forces to the tissue. The addition of
MB decreases the energy required to create cavitation and
increases the eﬀectiveness of cell membrane permeation and of
cell transfections (Delalande et al., 2013).
Microbubbles might also be used for gene therapy. Here, the
transport of genes or nucleic acids to and their introduction into
cells is facilitated by CEUS. Wang et al. (2008) showed that in
presence of MB the eﬃcacy of cell transfection was 1–2 orders of
magnitude higher than with plasmid DNA alone. However, the
eﬃcacy of US-mediated gene transfer is low in comparison to
electroporation or viral transfection. Thus, the group around Sun
intends to design MB, which are better suited for gene delivery
than the commercially available Deﬁnity R© . They increased the
lipid-shell acyl-chain length to enhance the bubble stability or
charged the spheres’ shell positively in order to improve DNA-
binding aﬃnity. Using the designedMB for gene transfection, the
group observed signiﬁcantly enhanced transfection eﬀectiveness
by stronger transgene expression compared to gene transfection
with Deﬁnity R© . Still, transfection eﬃcacy is not comparable
to viral transfection, but since US-mediated transfection using
MB contains less risks regarding immunotoxicity and possible
oncogenic eﬀects and provides a better spatial and temporal
control of the process, work in this ﬁeld will be continued (Sun
et al., 2014). Dewitte et al. (2014) also used a combination of
lipid MB and nucleic acids for transfections. In their setup,
mRNA coding for cancer antigens was bound to the lipid
bubbles. Application of US led to transfection of murine
dendritic cells ex vivo. These were later on injected, similar to
a vaccination, into lymph nodes near the tumors of nude mice.
The maturated antigen-presenting dendritic cells then lead to a
strong reduction of tumor mass, in some cases even complete
remission and long-term immunity to tumors expressing this
antigen (Dewitte et al., 2014). Similar to transfection studies
with MB, Yin et al. (2014) used NB to transfect cells in vitro
and in vivo with siRNA to enhance apoptosis in tumors
FIGURE 4 | Targeted MBs with entrapped drug/nucleic acids rupture under the US-induced acoustic pressure and release their loading specifically
at the side of a tumor (schematic illustration, not drawn to scale).
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FIGURE 5 | Effect of US only (US) and USPIO-labeled MB with US (USPIO-MB+US) on the BBB. T2∗-weighted MRI images were taken before and after
US/USPIO-MB+US application, R2∗ values of each measurement were color-coded and overlayed. The most striking difference can be seen after US application for
30 min, comparing pre- and post-scan in both groups (from: Lammers et al., 2015, ©2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim).
after NB injection and US treatment with promising ﬁrst
results.
The second application ﬁeld for bubble-enhanced
sonoporation is US-mediated drug release (Figure 4). Using
drug-loaded MB, it is possible to spatiotemporally apply LOFU
pulses at certain organs to increase the membrane permeability,
and at the same time increase the energy to promote bubble
collapse and particle release (Tzu-Yin et al., 2013). This way, the
group around Kiessling and co-workers used USPIO containing
PBCA-MB (USPIO-MB) as a proof of principle approach to
demonstrate drug delivery across the BBB in mice (Figure 5).
For the experiment, mice were scanned by MRI before and after
injection of USPIO-MB and successive US treatment in the head
region using destructive pulses. In comparison to control groups,
the USPIO brain incorporation was signiﬁcantly increased in the
group receiving US treatment. Drug delivery across the BBB was
additionally conﬁrmed by histology, and signiﬁcantly enhanced
FITC-dextran extravasation and deposition within the brain
was detected in animals receiving USPIO-MB and soniﬁcation.
The temporal and spatial BBB-opening oﬀers a new perspective
to treat gliomas, but also neurodegenerative disorders like
Alzheimer or Parkinson’s disease, where macromolecular drugs
or growth factors have to be locally accumulated (Lammers
et al., 2015). However, also outside of the brain US-supported
drug delivery is promising. In an animal model of incomplete
tumor resection, cetuximab-loaded MB and US stimulation
had stronger therapeutic eﬀects on the remaining tumor mass
than cetuximab-only treated animals, which was conﬁrmed by
in vivo ﬂuorescence and bioluminescence, as well as caliper
measurements (Sorace et al., 2014). Co-delivery of paclitaxel and
siRNA to inhibit anti-apoptotic protein production also showed
very promising results in a murine HepG2 tumor model. Here,
tumor growth was strongly inhibited in animals which received
NB with paclitaxel entrapped in and siRNA-containing micelles
attached to the shell, additionally to US application. Furthermore
those animals showed longer survival (Yin et al., 2014). Despite
those promising results further animal studies need to be done
before similar setups can go into clinical trials.
Besides being or delivering the therapeutic agents themselves,
MB were shown to be highly useful in monitoring of oncological
therapies. Shortly after chemotherapy started, Lassau et al.
(2005, 2006). could show changes in tumor vascularity or
increasing necrosis in patients with metastatic melanoma and
gastrointestinal stroma tumors after injection of Levovist R© and
SonoVue R©. Using standardized dynamic CEUS measurements,
the group was even able to predict the outcome of antiangiogenic
tumor therapy by evaluating the “area under the perfusion
curve.” Among several criteria, this one was found to be highly
correlated to therapy response and freedom from progression
(Lassau et al., 2014). Diﬀerentiation of responders and non-
responders at early points in time is needed to plan if the
therapy will be continued or if an alternative has to be
considered.
Conclusion
In this review we presented the historical development of CAs
for US imaging from the early steps to the current state of
the art. MBs are established CA for clinical vascular analysis
and liver diagnosis, but also other applications. A broad variety
of materials and sizes generates the basis for those multiple
diagnostic and therapeutic applications. Currently, there are
three clinically approved CAs, but with many on-going pre-
clinical studies and promising ﬁrst results, more clinical trials
can be expected to start within the next years. The combination
of US CAs for diagnostics and therapy in one single injection
therefore holds a great potential for the future and might
be a valuable tool for treatment of widespread and deadly
diseases like cancer or cardiovascular diseases. But also for
neurodegenerative diseases USCA might play a growing role in
treatment. A temporary increase in vessel permeability could
enhance drug delivery to the brain or other tumors while
reducing systemic side eﬀects due to the mostly local delivery.
USCAmight also gain more importance in non-invasive ablation
therapies.
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When functional analysis or tissue vascularization does not
suﬃce, the application of molecularly-targeted CA would be
complementary, both in diagnosis and targeted drug delivery.
For targeted MB and NB, the pre-clinically common biotin-
streptavidin linking method needs a similarly strong and easy
alternative to avoid immune reactions. Additionally, more
targets with a suﬃciently strong binding to the ligand are
required, otherwise the shear stress in vessels might inhibit
successful binding of the CAs and thus impair the contrast
enhancement. Another point that might need reﬁnement is
the CA’s circulation time. So far even PEGylated bubbles
with PFC have a very limited lifetime, limiting the time
frame for examination. But with no described long term
impairments after injection, rare side eﬀects and a valuable role in
diagnostics, sonothrombolysis, monitoring of treatment, speciﬁc
and targeted substance delivery vesicles or sonosensitizers, the
technology of CA and US in combination is –with some speciﬁc
adjustments- the swiss army knife among CAs and imaging
modalities.
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